Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
American Journal of Hematology|February 21, 2019
Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentationJuan Pablo Alderuccio, Wei Zhao, Amrita Desai, et al.
The Lancet. Haematology|December 11, 2024
Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trialJuan Pablo Alderuccio, Alvaro J Alencar, Jonathan H Schatz, et al.
JAMA Network Open|February 16, 2022
Comparison of Robot-Assisted and Open Radical Cystectomy in Recovery of Patient-Reported and Performance-Related Measures of Independence: A Secondary Analysis of a Randomized Clinical TrialVivek Venkatramani, Isildinha M Reis, Mark L Gonzalgo, et al.
Journal of Clinical Apheresis|November 24, 2025
Extracorporeal Photopheresis for Chronic Graft-Versus-Host Disease According to 2014 NIH Consensus CriteriaYitzhar Goretsky, Noa Holtzman, Sunwoo Han, et al.
The Canadian Journal of Urology|June 11, 2019
Validation of dominant and secondary sequence utilization in PI-RADS v2 for classifying prostatic lesionsNachiketh Soodana-Prakash, R Patricia Castillo, Isildinha M Reis, et al.
BJUI Compass|August 28, 2023
Optimum threshold of the 4Kscore for biopsy in men with negative or indeterminate multiparametric magnetic resonance imagingRicardo de Almeida S, Jamie Thomas, Matthew M Mason, et al.
Prostate Cancer and Prostatic Diseases|September 27, 2024
Evaluating 4Kscore's role in predicting progression on active surveillance for prostate cancer independently of clinical information and PIRADS scoreHelen Y Hougen, Isildinha M Reis, Sunwoo Han, et al.
The Journal of Urology|December 28, 2020
Heterogeneity in Genomic Risk Assessment from Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of Magnetic Resonance Imaging Targeted BiopsySanoj Punnen, Radka Stoyanova, Deukwoo Kwon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 17, 2012
Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivoFiona Simpkins, Pedro Hevia-Paez, Jun Sun, et al.
JAMA Network Open|October 8, 2024
Reproductive Risk Factor Patterns in Caribbean Women With Breast Cancer Across 4 GenerationsAlex P Sanchez-Covarrubias, Maurice J Chery, Priscilla Barreto-Coehlo, et al.
Pageof 12